There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report), Tempest Therapeutics (TPST – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments.
Bioxcel Therapeutics (BTAI)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics today and set a price target of $66.00. The company’s shares closed last Friday at $18.87.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bioxcel Therapeutics with a $45.29 average price target, a 128.7% upside from current levels. In a report issued on May 17, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Tempest Therapeutics (TPST)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Tempest Therapeutics, with a price target of $35.00. The company’s shares closed last Friday at $1.85.
According to TipRanks.com, Pantginis is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tempest Therapeutics with a $20.50 average price target.
Citius Pharmaceuticals (CTXR)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals, with a price target of $6.00. The company’s shares closed last Friday at $1.11.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.00 average price target, implying a 450.5% upside from current levels. In a report issued on May 22, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BTAI:
- BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
- BTAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioXcel Therapeutics management to meet with Truist
